• 1
    Moser M, Setaro J. Resistant or difficult to control hypertension. N Engl J Med. 2006;355:385392.
  • 2
    Cifkova R, Erdine S, Fagard R. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens. 2003;21:17791786.
  • 3
    Thorand B, Lowel H, Schneider A, et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984–1998. Arch Intern Med. 2003;163:9399.
  • 4
    Freeman DJ, Norrie J, Caslake MJ, et al. West of Scotland Coronary Prevention Study: C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2002;51:15961600.
  • 5
    Barzilay JI, Abraham L, Heckbert SR, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes. 2001;50:23842389.
  • 6
    Han TS, Sattar N, Williams K, et al. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care. 2002;25:20162021.
  • 7
    Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet. 1999;353:16491652.
  • 8
    Ford ES. Leukocyte count, erythrocyte sedimentation rate, and diabetes incidence in a national sample of US adults. Am J Epidemiol. 2002;155:5764.
  • 9
    Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327334.
  • 10
    Bozzoli C, Muscari A, Puddu GM, et al. Association of serum C3 and essential hypertension. G Ital Cardiol. 1992;22(12):13611366.
  • 11
    Schaadt O, Sorensen H, Krogsgaard AR. Association between the C3F-gene and essential hypertension. Clin Sci (Lond). 1981;61(suppl 7):363s365s.
  • 12
    Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106:913919.
  • 13
    Venugopal SK, Devaraj S, Yuhanna I, et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2002;106:14391441.
  • 14
    Vongpatanasin W, Thomas GD, Schwartz R, et al. C-reactive protein causes downregulation of vascular angiotensin subtype 2 receptors and systolic hypertension in mice. Circulation. 2007;115(8):10201028.
  • 15
    Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002;105:18901896.
  • 16
    Mahmud A, Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension. 2005;46(5):11181222.
  • 17
    Magen E, Viskoper R, Mishal J, et al. Resistant arterial hypertension and hyperlipidemia: atorvastatin, not vitamin C, for blood pressure control. Isr Med Assoc J. 2004;6(12):742746.
  • 18
    Ridker PM. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of lowdensity lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation. 2003;108:22922297.
  • 19
    Ritchie RF, Palomaki GE, Neveux LM, et al. Reference distributions for complement proteins C3 and C4: a practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal. 2004;18:18.
  • 20
    Moshage H. Cytokines and the hepatic acute phase response. J Pathol. 1997;181:257266.
  • 21
    Gabrielsson BG, Johansson JM, Lönn M, et al. High expression of complement components in omental adipose tissue in obese men. Obes Res. 2003;11:699708.
  • 22
    Engstrom G, Hedblad B, Berglund G, et al. Plasma levels of complement C3 is associated with development of hypertension: a longitudinal cohort study. J Hum Hypertens. 2007;21(4):276282.
  • 23
    Tomaszewski M, Zukowska-Szczechowska E, Grzeszczak W. Evaluation of complement component C4 concentration and immunoglobulins IgA, IgG, and IgM in serum of patients with primary essential hypertension. Pol Arch Med Wewn. 2000;103(5–6):247251.
  • 24
    Palikhe A, Sinisalo J, Seppänen M, et al. Serum complement C3/C4 ratio, a novel marker for recurrent cardiovascular events. Am J Cardiol. 2007;99(7):890895.
  • 25
    Alper CA, Johnson AM, Birtch AG, et al. Human C’3: evidence for the liver as the primary site of synthesis. Science. 1969;163(864):286288.
  • 26
    Kulics J, Colten HR, Perlmutter DH. Counterregulatory effects of interferon-gamma and endotoxin on expression of the human C4 genes. J Clin Invest. 1990;85(3):943949.
  • 27
    Ueki A, Sai T, Oka H, et al. Biosynthesis and secretion of the third component of complement by human endothelial cells in vitro. Immunology. 1987;61(1):1114.
  • 28
    Ueda Y, Nagasawa K, Tsukamoto H, et al. Production of the third and fourth component of complement (C3, C4) by smooth muscle cells. Immunology. 1996;89(2):183188.
  • 29
    Lin ZH, Fukuda N, Jin XQ, et al. Complement 3 is involved in the synthetic phenotype and exaggerated growth vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension. 2004;44:4247.
  • 30
    Major outcomes in highrisk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:29812997.
  • 31
    Cushman WC, Ford CE, Cutler JA. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393404.
  • 32
    Black HR, Elliott WJ, Grandits G. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289: 20732082.
  • 33
    Julius S, Kjeldsen SE, Brunner H. VALUE trial: long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens. 2003;16:544548.
  • 34
    Salles GF, Fiszman R, Cardoso CR, et al. Relation of left ventricular hypertrophy with systemic inflammation and endothelial damage in resistant hypertension. Hypertension. 2007;50(4):723728.